● Breaking

IVIG Boosts Treatment for Inflammatory Myopathies, Study Finds

IVIG Boosts Treatment for Inflammatory Myopathies, Study Finds - inflammatory myopathies
A study published in JAMA Neurology assessed 44 patients with inflammatory myopathies between 2021 and 2025.

A new study from the Netherlands shows that adding intravenous immunoglobulin (IVIG) to prednisone treatment significantly improves outcomes for patients with newly diagnosed inflammatory myopathies. The research, published in JAMA Neurology, focused on adults with conditions like dermatomyositis and polymyositis. Conducted between September 2021 and September 2025, the trial assessed 94 patients, of whom 50 were excluded or declined participation, leaving 44 patients to enter the study.

IVIG Enhances Treatment for Autoimmune Disorders

The double-blind, placebo-controlled trial involved 42 patients at a tertiary referral center specializing in idiopathic inflammatory myopathies (IIMs). Participants received high-dose prednisone at 1 mg/kg/day, up to 80 mg daily, and were randomly assigned to either IVIG at 2.0 g/kg body weight or a placebo at baseline, week 4, and week 8. The study aimed to assess if IVIG could improve clinical outcomes faster than corticosteroids alone, which remain a key but sometimes insufficient initial treatment for IIMs.

Results showed that patients receiving IVIG had a mean Total Improvement Score (TIS) of 60.0 at 12 weeks, compared to 42.5 in the placebo group. Moderate improvement was seen in 91% of IVIG patients versus 53% in the placebo group. Major improvement occurred in 70% of IVIG patients, compared to 26% in the placebo group. The TIS, a composite measure of six disease activity domains, highlighted IVIG’s superior efficacy in reducing inflammation and muscle damage.

Faster Response Times with IVIG

Patients on IVIG reached a moderate response in a median time of 4 weeks, compared to 12 weeks for those on placebo. However, the study noted one case of asymptomatic deep venous thrombosis in the IVIG group, highlighting the need to monitor thromboembolic risks, a known complication of IVIG therapy. This finding shows the importance of careful patient selection and ongoing safety assessments.

Implications for Patients and Clinicians

The research, led by Pinar Özkaynar of the Amsterdam University Medical Center, adds to the growing body of evidence supporting IVIG’s role in managing autoimmune disorders. Published online on September 14, 2026 (doi:10.1001/jamaneurol.2026.3088), the study emphasizes the balance between IVIG’s benefits and its potential risks as clinicians consider incorporating it into treatment plans.